NCT05502315 - Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 2, 2023

Primary Completion Date

April 12, 2026

Study Completion Date

April 12, 2027

Conditions

Castration-resistant Prostate CancerMetastatic Cancer

Interventions

DRUG

Cabozantinib

40 mg taken orally

DRUG

Nivolumab

480 mg by infusion

Trial Locations (4)

RECRUITING

University of Wisconsin, Madison

RECRUITING

University of Chicago Medical Center, Chicago

RECRUITING

University of Texas Southwestern Medical Center, Dallas

RECRUITING

University of California San Diego, La Jolla